Novartis participated successfully in the iPiE project (Intelligence-led Assessment of Pharmaceuticals in the Environment), funded by the Innovative Medicines Initiative (IMI). The IMI is a public-private partnership between pharmaceutical companies, the European Commission and the European Federation of Pharmaceutical Industries and Associations (EFPIA). This project developed a framework to identify the potential risk of pharmaceuticals to the natural environment and methods to prioritize legacy pharmaceuticals for targeted environmental risk assessment. Following the success of iPiE, Novartis joined IMI-PREMIER, a 6-year project with the IMI, focused on evaluating and mitigating risk of medicines in the environment. The PREMIER (Prioritisation and Risk Evaluation of Medicines in the EnviRonment) project aims to deliver an innovative framework for characterizing the environmental risks of active pharmaceutical ingredients (APIs), which can ultimately be used to explore and promote greener drug design.
In India, we are working with local partners and communities in the State of Telangana to implement an innovative watershed project that aims to be a sustainable solution for the industry, while also having a positive impact on society in general. In addition, as an active member of the Pharmaceutical Supply Chain Initiative, we are supporting the State of Telangana’s efforts to revitalize the Musi River, a vital water source to the Hyderabad area which has been impacted by poor wastewater management.
For further information, please see: